CARSGEN-B (02171) plans to repurchase approximately 25.46 million shares and receive 100,000 shares from major shareholders.

CARSGEN-B (02171) announced that the existing share repurchase plan has been updated by the company's board of directors to repurchase up to 25,461,295 shares on the open market within 50 Hong Kong trading days starting from November 13, 2025. The 25,461,295 shares under the updated share repurchase plan, together with the shares already repurchased in 2025, will amount to 5% of the total number of shares issued on the day of granting the 2025 share repurchase authorization. The board believes that the company's current stock price is below its true value and does not fully reflect its business prospects. The board believes that the share repurchase plan demonstrates the confidence of the directors and senior management in the long-term growth and market performance of the company. The board also believes that the share repurchase plan is in the overall best interests of the company and its shareholders. The board has recently been informed that BJ BioTech Holdings Limited and its concerted parties (collectively referred to as the "BJ Concerted Group") have collectively purchased 100,000 shares between November 6, 2025, and November 10, 2025. Following the shareholding increase, the BJ Concerted Group holds 218,048,730 shares, representing approximately 37.92% of the total number of shares issued as of the date of this announcement (excluding treasury shares).